Literature DB >> 12212775

NAP accelerates the performance of normal rats in the water maze.

Illana Gozes1, Roy Alcalay, Eliezer Giladi, Albert Pinhasov, Sharon Furman, Douglas E Brenneman.   

Abstract

NAP (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) has neuroprotective, memory enhancing, and neurotrophic properties. NAP is a short peptide sequence derived from the recently cloned, activity-dependent neuroprotective protein. The current study was designed to evaluate NAP activity in normal middle-aged animals to further assess NAP's breadth of neuroprotection. NAP was administered by inhalation. Results showed that in the paradigm of the Morris water maze, assessing short-term memory, only the NAP-treated middle-aged rats and not placebo-treated rats showed significant improvements by the end of the testing period. These results suggest efficacy for NAP in normal aging that is associated with accumulating environmental and genetic toxic factors.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12212775     DOI： 10.1007/s12031-002-0028-0

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN： 0895-8696            Impact factor:   3.444


  15 in total

1.  A novel peptide prevents death in enriched neuronal cultures.

Authors:  I Zemlyak; S Furman; D E Brenneman; I Gozes
Journal:  Regul Pept       Date:  2000-12-22

Review 2.  A new concept in the pharmacology of neuroprotection.

Authors:  I Gozes; D E Brenneman
Journal:  J Mol Neurosci       Date:  2000 Feb-Apr       Impact factor: 3.444

3.  Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.

Authors:  D Offen; Y Sherki; E Melamed; M Fridkin; D E Brenneman; I Gozes
Journal:  Brain Res       Date:  2000-01-31       Impact factor: 3.252

Review 4.  A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein.

Authors:  I Gozes; M Bassan; R Zamostiano; A Pinhasov; A Davidson; E Giladi; O Perl; G W Glazner; D E Brenneman
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

5.  A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice.

Authors:  L Beni-Adani; I Gozes; Y Cohen; Y Assaf; R A Steingart; D E Brenneman; O Eizenberg; V Trembolver; E Shohami
Journal:  J Pharmacol Exp Ther       Date:  2001-01       Impact factor: 4.030

6.  Cloning and characterization of the human activity-dependent neuroprotective protein.

Authors:  R Zamostiano; A Pinhasov; E Gelber; R A Steingart; E Seroussi; E Giladi; M Bassan; Y Wollman; H J Eyre; J C Mulley; D E Brenneman; I Gozes
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

7.  A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis.

Authors:  Jacob Romano; Liana Beni-Adani; Orlev Levy Nissenbaum; Douglas E Brenneman; Esther Shohami; Illana Gozes
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

8.  Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze.

Authors:  I Gozes; E Giladi; A Pinhasov; A Bardea; D E Brenneman
Journal:  J Pharmacol Exp Ther       Date:  2000-06       Impact factor: 4.030

Review 9.  Pharmaceutical VIP: prospects and problems.

Authors:  I Gozes; M Fridkinb; J M Hill; D E Brenneman
Journal:  Curr Med Chem       Date:  1999-11       Impact factor: 4.530

10.  Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide.

Authors:  D E Brenneman; E A Neale; G A Foster; S W d'Autremont; G L Westbrook
Journal:  J Cell Biol       Date:  1987-06       Impact factor: 10.539
View more
  8 in total

1.  A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.

Authors:  Sheila M Fleming; Caitlin K Mulligan; Franziska Richter; Farzad Mortazavi; Vincent Lemesre; Carmen Frias; Chunni Zhu; Alistair Stewart; Illana Gozes; Bruce Morimoto; Marie-Françoise Chesselet
Journal:  Mol Cell Neurosci       Date:  2010-12-27       Impact factor: 4.314

2.  Intranasal Delivery of Recombinant NT4-NAP/AAV Exerts Potential Antidepressant Effect.

Authors:  Xian-Cang Ma; Zheng Chu; Xiao-Ling Zhang; Wen-Hui Jiang; Min Jia; Yong-Hui Dang; Cheng-Ge Gao
Journal:  Neurochem Res       Date:  2016-02-04       Impact factor: 3.996

3.  Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides.

Authors:  Jingwei Li; Chi Zhang; Jing Li; Li Fan; Xinguo Jiang; Jun Chen; Zhiqing Pang; Qizhi Zhang
Journal:  Pharm Res       Date:  2013-04-03       Impact factor: 4.200

4.  NAP mechanisms of neuroprotection.

Authors:  Illana Gozes; Ruth A Steingart; Avron D Spier
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

5.  Brain injury-dependent expression of activity-dependent neuroprotective protein.

Authors:  Roy Zaltzman; Alexander Alexandrovich; Sara M Beni; Victoria Trembovler; Esther Shohami; Illana Gozes
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

6.  Notch signalling in adult neurons: a potential target for microtubule stabilization.

Authors:  Sara Anna Bonini; Giulia Ferrari-Toninelli; Mery Montinaro; Maurizio Memo
Journal:  Ther Adv Neurol Disord       Date:  2013-11       Impact factor: 6.570

7.  Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome.

Authors:  Gal Hacohen-Kleiman; Shlomo Sragovich; Gidon Karmon; Andy Y L Gao; Iris Grigg; Metsada Pasmanik-Chor; Albert Le; Vlasta Korenková; R Anne McKinney; Illana Gozes
Journal:  J Clin Invest       Date:  2018-09-24       Impact factor: 14.808

Review 8.  From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.

Authors:  Illana Gozes; Inna Divinsky; Inbar Pilzer; Mati Fridkin; Douglas E Brenneman; Avron D Spier
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.